TY - JOUR
T1 - KNOW-KT (KoreaN cohort study for outcome in patients with kidney transplantation: A 9-year longitudinal cohort study)
T2 - Study rationale and methodology
AU - Yang, Jaeseok
AU - Lee, Joongyup
AU - Huh, Kyu Ha
AU - Park, Jae Berm
AU - Cho, Jang Hee
AU - Lee, Sik
AU - Ro, Han
AU - Han, Seung Yeup
AU - Kim, Young Hoon
AU - Jeong, Jong Cheol
AU - Park, Byung Joo
AU - Han, Duck Jong
AU - Park, Sung Bae
AU - Chung, Wookyung
AU - Park, Sung Kwang
AU - Kim, Chan Duck
AU - Kim, Sung Joo
AU - Kim, Yu Seun
AU - Ahn, Curie
N1 - Funding Information:
We thank all patients who participate in the KNOW-KT, and all the colleagues who contribute to the operation of the study. This research was supported by a fund (2013E3301601) from Korea Centers for Disease Control and Prevention after peer-review by Korea Centers for Disease Control and Prevention.
PY - 2014/5/9
Y1 - 2014/5/9
N2 - Background: Asian patients undergoing kidney transplantation (KT) generally have better renal allograft survival and a lower burden of cardiovascular disease than those of other racial groups. The KNOW-KT aims to explore allograft survival rate, cardiovascular events, and metabolic profiles and to elucidate the risk factors in Korean KT patients. Methods. KNOW-KT is a multicenter, observational cohort study encompassing 8 transplant centers in the Republic of Korea. KNOW-KT will enroll 1,000 KT recipients between 2012 and 2015 and follow them up to 9 years. At the time of KT and at pre-specified intervals, clinical information, laboratory test results, and functional and imaging studies on cardiovascular disease and metabolic complications will be recorded. Comorbid status will be assessed by the age-adjusted Charlson co-morbidity index. Medication adherence and information on quality of life (QoL) will be monitored periodically. The QoL will be assessed by the Kidney Disease Quality of Life Short Form. Donors will include both living donors and deceased donors whose status will be assessed by the Kidney Donor Risk Index. Primary endpoints include graft loss and patient mortality. Secondary endpoints include renal functional deterioration (a decrease in eGFR to <30 mL/min/1.73 m 2), acute rejection, cardiovascular event, albuminuria, new-onset diabetes after transplant, and QoL. Data on other adverse outcomes including episodes of infection, malignancy, recurrence of original renal disease, fracture, and hospitalization will also be collected. A bio-bank has been established for the acquisition of DNA, RNA, and protein from serum and urine samples of recipients at regular intervals. Bio-samples from donors will also be collected at the time of KT. KNOW-KT was registered in an international clinical trial registry (NCT02042963 at) on January 20th, 2014. Conclusion: The KNOW-KT, the first large-scale cohort study in Asian KT patients, is expected to represent the Asian KT population and provide information on their natural course, complications, and risk factors for complications.
AB - Background: Asian patients undergoing kidney transplantation (KT) generally have better renal allograft survival and a lower burden of cardiovascular disease than those of other racial groups. The KNOW-KT aims to explore allograft survival rate, cardiovascular events, and metabolic profiles and to elucidate the risk factors in Korean KT patients. Methods. KNOW-KT is a multicenter, observational cohort study encompassing 8 transplant centers in the Republic of Korea. KNOW-KT will enroll 1,000 KT recipients between 2012 and 2015 and follow them up to 9 years. At the time of KT and at pre-specified intervals, clinical information, laboratory test results, and functional and imaging studies on cardiovascular disease and metabolic complications will be recorded. Comorbid status will be assessed by the age-adjusted Charlson co-morbidity index. Medication adherence and information on quality of life (QoL) will be monitored periodically. The QoL will be assessed by the Kidney Disease Quality of Life Short Form. Donors will include both living donors and deceased donors whose status will be assessed by the Kidney Donor Risk Index. Primary endpoints include graft loss and patient mortality. Secondary endpoints include renal functional deterioration (a decrease in eGFR to <30 mL/min/1.73 m 2), acute rejection, cardiovascular event, albuminuria, new-onset diabetes after transplant, and QoL. Data on other adverse outcomes including episodes of infection, malignancy, recurrence of original renal disease, fracture, and hospitalization will also be collected. A bio-bank has been established for the acquisition of DNA, RNA, and protein from serum and urine samples of recipients at regular intervals. Bio-samples from donors will also be collected at the time of KT. KNOW-KT was registered in an international clinical trial registry (NCT02042963 at) on January 20th, 2014. Conclusion: The KNOW-KT, the first large-scale cohort study in Asian KT patients, is expected to represent the Asian KT population and provide information on their natural course, complications, and risk factors for complications.
UR - http://www.scopus.com/inward/record.url?scp=84901006403&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84901006403&partnerID=8YFLogxK
U2 - 10.1186/1471-2369-15-77
DO - 10.1186/1471-2369-15-77
M3 - Article
C2 - 24884405
AN - SCOPUS:84901006403
SN - 1471-2369
VL - 15
JO - BMC Nephrology
JF - BMC Nephrology
IS - 1
M1 - 77
ER -
